We are committed to improving health and well-being around the world. From developing new therapies that treat and prevent disease to helping people in need, we are guided by a rich legacy and inspired by a shared vision.
With an enduring focus on innovation and sound science, we work to deliver vaccines, medications, and consumer and animal health products that can help millions around the world.
Oncology Information Center
Initial commitment of $6 million dedicated to addressing growing U.S. problem
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Merck for Mothers has launched programs aimed at decreasing the number of women across the United States who die from or suffer severe complications related to pregnancy and childbirth.
The maternal mortality rate in this country has nearly doubled since 1990, despite significant progress in reducing rates globally. In addition, more than 50,000 women a year in the United States – one every 10 minutes – nearly die from a severe complication they experience during pregnancy or childbirth.
“The rate of maternal mortality is increasing here in the United States. The tragedy is that many of these deaths are actually preventable,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “Merck is working with partners around the globe to help improve the situation everywhere, including in the United States, to create a world where no woman dies while giving life.”
With work already under way in more than 20 countries including Brazil, India, Senegal, Uganda and Zambia, Merck for Mothers is now working in the United States to address the following areas:
In the United States, Merck for Mothers is partnering with: the American Congress of Obstetricians and Gynecologists, District II; the Association of Maternal and Child Health Programs; the Association of Women’s Health, Obstetric and Neonatal Nurses; Baltimore Healthy Start; California Maternal Quality Care Collaborative; Camden Coalition of Healthcare Providers; Maternity Care Coalition; and the Northern Manhattan Perinatal Partnership.
About Merck for Mothers
Merck for Mothers is a 10-year, $500 million initiative focused on creating a world where no woman has to die from complications of pregnancy and childbirth. Drawing on the company's history of discovering innovative, life-saving medicines and vaccines, Merck for Mothers is applying Merck's scientific and business expertise – as well as its financial resources and experience in taking on tough global healthcare challenges – to reduce maternal mortality around the world. For more information, visit www.merckformothers.com and connect with us on Facebook.
Merck for Mothers Collaborations in the U.S.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
# # #
To download multimedia assets, click here to view the Multimedia News Release on MultiVu.
Jennifer Allen Woodruff